Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Nvidia Develops New Location-Verification Technology for AI Chips 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Drugmaker Merck has partnered with Daiichi Sankyo, under which it will pay $5.5 billion to develop three candidate cancer drugs jointly. This deal could be worth up to $22 billion for Daiichi Sankyo, depending on the success of the therapies.
Shares of Daiichi Sankyo soared by 14.4% in Tokyo, marking their largest gain in over a year. Merck also saw a rise of 1.6% in morning trading.
Ambitious Revenue Target for Daiichi Sankyo's Oncology Business
According to Reuters, Daiichi Sankyo has set a revenue target of at least 900 billion yen ($6 billion) for its oncology business by the fiscal year ending March 31, 2026. This would represent an impressive five-fold increase over three years.
Investopedia noted that the three-drug candidates to be developed with Merck fall into the antibody-drug conjugates (ADC) class, with various stages of clinical development for treating multiple solid cancer tumors. Unlike conventional chemotherapy, ADCs are designed to target cancer cells, minimizing damage to healthy cells specifically.
"One of the changes in the external environment is intensifying competition in ADC development," Daiichi Sankyo CEO Sunao Manabe said, describing the company's decision to seek a partner.
Promising Commercial Revenue Potential
The drug candidates - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan - hold significant worldwide commercial revenue potential for both companies by the mid-2030s, according to Merck and Daiichi Sankyo.
Under the agreement, Merck and Daiichi Sankyo will jointly develop and potentially commercialize the drug candidates globally, except in Japan, where Daiichi Sankyo will retain exclusive rights. Daiichi Sankyo will be responsible for manufacturing and supply.
Merck Gains Access to Daiichi Sankyo's Expertise in the ADC Space
The partnership allows Merck to tap into Daiichi Sankyo's leadership status in the ADC field. Analysts believe this collaboration will strengthen Merck's cancer drug portfolio, particularly as its top-selling Keytruda faces patent expiration at the end of the decade.
In return for the collaboration, Merck will make an upfront payment of $4 billion to Daiichi Sankyo, followed by $1.5 billion in continuation payments over the next two years. Additionally, Merck may pay up to $16.5 billion based on future sales milestones, amounting to $5.5 billion for each product.
Daiichi Sankyo has six ADC candidates in its pipeline, including two jointly developed with AstraZeneca. However, this week's disappointing data abstract on the late-stage trial of datopotamab deruxtecan, developed with AstraZeneca, has impacted analysts' expectations.
Photo: Merck Media
